Dolby Laboratories Inc SEC Filings

DLB has filed a Rule 144 notice for the planned sale of 26,766 common shares through Morgan Stanley Smith Barney on the NYSE around 12/16/2025, with an aggregate market value of $1,786,309.31.

The shares to be sold come from 18,017 restricted stock and 8,749 performance shares acquired from the issuer on 12/15/2025, and the filing notes 60,845,846 common shares outstanding. It also lists prior sales over the past three months by the Yeaman Family Trust of 34,367, 36,699 and 25,000 common shares, with gross proceeds of $2,305,493.01, $2,455,401.64 and $1,721,840.00, respectively.

Mark Andrew Sherman filed a notice under Rule 144 to sell 9,109 shares of DLB common stock. The planned sale, through Morgan Stanley Smith Barney on the NYSE, has an aggregate market value of $607,849.04 and is expected around 12/16/2025. For this class of stock, 60,845,846 shares were reported as outstanding.

The securities to be sold consist of restricted stock and performance shares acquired from the issuer on 12/15/2025. Over the prior three months, Sherman also sold 4,500 common shares on 12/01/2025, generating gross proceeds of $304,035.75.

Dolby Laboratories, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on February 3, 2026, including the election of eight directors, an advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor.

For fiscal 2025, Dolby reports total revenue of $1.35 billion versus $1.27 billion in 2024, a 6.3% increase, while net income was $255.0 million versus $261.8 million, a 2.6% decline. Non‑GAAP net income rose to $413.5 million and non‑GAAP diluted EPS to $4.24. Diluted EPS was $2.62, the year‑end share price was $72.39, and in November 2025 the quarterly dividend was raised 9%, from $0.33 to $0.36 per share.

The proxy describes a pay‑for‑performance program that kept named executive officer base salaries flat for 2025 and ties annual bonuses to revenue and non‑GAAP operating income. For fiscal 2025, non‑GAAP operating income of $447.5 million and revenue of $1,349.1 million produced payouts at 94% of target bonuses. Long‑term incentives are primarily equity awards, including performance stock units that vested at 70.37% of target for the 2022–2025 cycle based on relative total stockholder return.

Dolby Laboratories, Inc. executive John Couling, senior vice president of Entertainment, reported selling 7,273 shares of Class A common stock at $68.75 per share on 12/11/2025.

After this insider sale, he beneficially owned 108,065 Class A shares directly, including 48,526 shares underlying restricted stock units that are subject to forfeiture until they vest.

Dolby Laboratories, Inc. President and CEO Kevin Yeaman, who is also a director, reported option exercises and related share sales involving the company’s Class A common stock on 12/09/2025. Through the Kevin and Rachel Yeaman Family Trust, he exercised employee stock options for 10,615 shares at an exercise price of $64.6 and 23,752 shares at $45.5, then sold 28,168 shares at a weighted average price of $66.9919 and 6,199 shares at a weighted average price of $67.5052.

Following these transactions, the trust continued to hold Class A shares, and Yeaman also had 127,735 shares underlying restricted stock units that remain subject to vesting conditions, along with a small indirect holding reported as held by a son. The reported options were fully vested at exercise and now show no remaining derivative securities held through the trust.

An insider associated with DLB has filed a Form 144 notice to sell 7,273 shares of common stock through Morgan Stanley Smith Barney LLC on or about 12/11/2025 on the NYSE, with an indicated aggregate market value of $500,018.75. These shares were originally acquired as restricted stock from the issuer in three grants dated 08/10/2014, 12/15/2016, and 12/15/2018.

The notice also reports that 6,164 common shares were sold on 11/20/2025 for gross proceeds of $407,563.68. Shares of the issuer’s common stock outstanding were 60,845,846 as of the data shown; this is a baseline figure, not the amount being sold.

Dolby Laboratories shareholder plans new stock sale under Rule 144. A filing reports an intention to sell 34,367 shares of Dolby common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,305,493.01. Dolby had 60,845,846 shares of common stock outstanding.

The 34,367 shares were acquired on 12/09/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the past three months, the Yeaman Family Trust has sold additional Dolby common shares in three transactions of 36,699, 25,000, and 25,000 shares, generating gross proceeds of $2,455,401.64, $1,721,840.00, and $1,791,487.50, respectively.

Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of $64.6 per share and acquired these shares.

On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of $67.5635 per share in multiple transactions. Following these transactions, he beneficially owned 62,397 shares of Class A common stock, which include 45,470 shares underlying restricted stock units that remain subject to forfeiture until they vest.